Unknown

Dataset Information

0

Cyclisation increases the stability of the sea anemone peptide APETx2 but decreases its activity at acid-sensing ion channel 3.


ABSTRACT: APETx2 is a peptide isolated from the sea anemone Anthopleura elegantissima. It is the most potent and selective inhibitor of acid-sensing ion channel 3 (ASIC3) and it is currently in preclinical studies as a novel analgesic for the treatment of chronic inflammatory pain. As a peptide it faces many challenges in the drug development process, including the potential lack of stability often associated with therapeutic peptides. In this study we determined the susceptibility of wild-type APETx2 to trypsin and pepsin and tested the applicability of backbone cyclisation as a strategy to improve its resistance to enzymatic degradation. Cyclisation with either a six-, seven- or eight-residue linker vastly improved the protease resistance of APETx2 but substantially decreased its potency against ASIC3. This suggests that either the N- or C-terminus of APETx2 is involved in its interaction with the channel, which we confirmed by making N- and C-terminal truncations. Truncation of either terminus, but especially the N-terminus, has detrimental effects on the ability of APETx2 to inhibit ASIC3. The current work indicates that cyclisation is unlikely to be a suitable strategy for stabilising APETx2, unless linkers can be engineered that do not interfere with binding to ASIC3.

SUBMITTER: Jensen JE 

PROVIDER: S-EPMC3407927 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Cyclisation increases the stability of the sea anemone peptide APETx2 but decreases its activity at acid-sensing ion channel 3.

Jensen Jonas E JE   Mobli Mehdi M   Brust Andreas A   Alewood Paul F PF   King Glenn F GF   Rash Lachlan D LD  

Marine drugs 20120716 7


APETx2 is a peptide isolated from the sea anemone Anthopleura elegantissima. It is the most potent and selective inhibitor of acid-sensing ion channel 3 (ASIC3) and it is currently in preclinical studies as a novel analgesic for the treatment of chronic inflammatory pain. As a peptide it faces many challenges in the drug development process, including the potential lack of stability often associated with therapeutic peptides. In this study we determined the susceptibility of wild-type APETx2 to  ...[more]

Similar Datasets

| S-EPMC3743484 | biostudies-literature
| S-EPMC3407934 | biostudies-literature
| S-EPMC391081 | biostudies-literature
| S-EPMC3378363 | biostudies-literature
| S-EPMC4144671 | biostudies-literature
| S-EPMC5848173 | biostudies-literature
| S-EPMC5517604 | biostudies-literature
2022-09-14 | GSE154477 | GEO
| S-EPMC5935648 | biostudies-literature
| S-EPMC2843212 | biostudies-literature